Liaw Yun-Fan
Liver Research Unit, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taipei, Taiwan.
Antivir Ther. 2009;14(1):13-22.
Studies published to date regarding on-treatment outcome prediction during chronic hepatitis B therapy were reviewed. Studies have shown that initial virological responses in terms of week 24 serum hepatitis B virus (HBV) DNA levels are associated with therapeutic outcomes of 1-year pegylated interferon-alpha and entecavir therapy, and weeks 52 or 104 of lamivudine and telbuvudine therapy. HBV DNA levels at week 48 are also associated with long-term adefovir therapy outcomes. Conceptual on-treatment adjustment and strategies have been proposed; however, this approach seems only necessary during therapy with nucleos(t)ide analogues with substantial risk of drug resistance. In addition, studies are needed to decide whether switching to or adding on a second drug, and with which drug, is the most cost-effective strategy.
对迄今发表的关于慢性乙型肝炎治疗期间治疗结果预测的研究进行了综述。研究表明，就第24周血清乙型肝炎病毒（HBV）DNA水平而言的初始病毒学反应与1年聚乙二醇化干扰素-α和恩替卡韦治疗、拉米夫定和替比夫定治疗第52周或104周的治疗结果相关。第48周的HBV DNA水平也与阿德福韦长期治疗结果相关。已经提出了概念性的治疗调整和策略；然而，这种方法似乎仅在使用有显著耐药风险的核苷（酸）类似物治疗期间才是必要的。此外，需要开展研究以确定换用或加用第二种药物以及使用哪种药物是最具成本效益的策略。
